Clinical Research Papers:
Prognosis of subtypes of the mucinous breast carcinoma in Chinese women: a population-based study of 32-year experience (1983-2014)
Metrics: PDF 1998 views | HTML 4330 views | ?
Abstract
Bo Pan1,*, Ru Yao1,*, Jie Shi2,*, Qian-Qian Xu1, Yi-Dong Zhou1, Feng Mao1, Yan Lin1, Jing-Hong Guan1, Xue-Jing Wang1, Yan-Na Zhang1, Xiao-Hui Zhang1, Song-Jie Shen1, Ying Zhong1, Ya-Li Xu1, Qing-Li Zhu3, Zhi-Yong Liang2 and Qiang Sun1
1 Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China
2 Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China
3 Department of Ultrasound, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China
* These authors have contributed equally to this work
Correspondence to:
Qiang Sun, email:
Keywords: mucinous breast cancer, subtype, prognosis
Received: February 21, 2016 Accepted: April 04, 2016 Published: April 18, 2016
Abstract
Purpose: The heterogeneous nature of the mucinous breast cancer (MBC), with its pure (PMBC) and mixed subtypes (MMBC), calls for precise prognosis assessment.
Methods: We analyzed 197 consecutive MBC patients, including 117 PMBC and 80 MMBC, who were treated from 1983 to 2014. The clinicopathological features, treatment choice, disease-free survival (DFS) and overall survival (OS) were compared among PMBC, MMBC and MMBC subgroups. Prognostic factors of PMBC and MMBC were identified.
Results: Compared to PMBC, MMBC had more lymph node metastasis (p = 0.043), Her2 positivity (p = 0.036), high Ki-67 index (defined as>20%, p = 0.026) and anti-Her2 targeted therapy (p = 0.016). The 5-year DFS of PMBC and MMBC were 90.4% and 86.2%, whereas the 5-year OS were 99.0% and 98.7%. No significant difference was found in DFS or OS among all MBC subtypes. High Ki-67 (p = 0.020) appeared as DFS factor in PMBC, while anti-Her2 targeted therapy (p = 0.047) as the DFS predictors in MMBC.
Conclusion: MMBC manifested similar 5-year survival to PMBC in Chinese woman, suggesting that intra-tumoral heterogeneity might not interfere with MBC short-term prognosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8778